Literature DB >> 23463806

Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study.

Simone Parisi, Clara L Peroni, Angela Laganà, Marco Scarati, Federico Ambrogio, Maria Bruzzone, Enrico Fusaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23463806     DOI： 10.1093/rheumatology/ket019

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

1.  Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study.

Authors:  Lorinda Chung; Katharine Ball; Aaliya Yaqub; Bharathi Lingala; David Fiorentino
Journal:  J Am Acad Dermatol       Date:  2014-08       Impact factor: 11.527

Review 2.  Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH).

Authors:  Rahul G Argula; Celine Ward; Carol Feghali-Bostwick
Journal:  Ther Clin Risk Manag       Date:  2019-12-13       Impact factor: 2.423

Review 3.  Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.

Authors:  Djúlio César Zanin-Silva; Maynara Santana-Gonçalves; Marianna Yumi Kawashima-Vasconcelos; Maria Carolina Oliveira
Journal:  Front Med (Lausanne)       Date:  2021-12-22

4.  Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.

Authors:  Kengo Akashi; Jun Saegusa; Sho Sendo; Keisuke Nishimura; Takuya Okano; Keiko Yagi; Masashi Yanagisawa; Noriaki Emoto; Akio Morinobu
Journal:  Arthritis Res Ther       Date:  2016-05-21       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.